Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and...

Area of Science:

• Oncology
• Immunotherapy
• Medical Oncology

Background:

• Immune-checkpoint inhibitor (ICI)-based therapy has transformed advanced non-small cell lung cancer (aNSCLC) treatment.
• However, a significant portion of patients experience primary or secondary resistance to first-line ICI therapy.
• Identifying resistance biomarkers and effective retreatment strategies remain critical challenges.

Purpose of the Study:

• To review current and emerging therapeutic strategies for aNSCLC patients progressing on first-line ICI therapy.
• To differentiate treatment approaches based on disease progression patterns: oligoprogression versus systemic progression.
• To discuss personalized treatment adaptation based on tumor re-characterization and prior ICI response.

Main Methods:

• Literature review of clinical trials and research studies on ICI therapy in aNSCLC.
• Analysis of treatment outcomes based on progression patterns (oligoprogression vs. systemic progression).
• Discussion of novel therapeutic strategies, including local ablative approaches and systemic treatments.

Main Results:

• Local ablative therapies are effective for oligoprogressive disease in patients receiving immunotherapy.
• Personalized treatment strategies can be developed for systemic progression based on tumor re-evaluation.
• Further research is needed to identify biomarkers for primary resistance and optimize retreatment protocols.

Conclusions:

• Optimizing treatment beyond first-line ICI therapy in aNSCLC requires careful consideration of progression patterns.
• Personalized approaches, integrating tumor re-characterization and response to prior therapy, are essential.
• Future research should focus on overcoming ICI resistance and improving long-term outcomes for aNSCLC patients.